Pulse Biosciences (PLSE) to Release Earnings on Wednesday

Pulse Biosciences (NASDAQ:PLSE) is projected to release its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect Pulse Biosciences to post earnings of ($0.31) per share and revenue of $0.50 million for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02).

Pulse Biosciences Price Performance

Shares of PLSE stock opened at $16.93 on Monday. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -16.12 and a beta of 1.79. Pulse Biosciences has a one year low of $13.77 and a one year high of $25.00. The company’s fifty day moving average price is $17.06 and its 200-day moving average price is $16.52.

Analysts Set New Price Targets

A number of analysts have issued reports on PLSE shares. Oppenheimer started coverage on shares of Pulse Biosciences in a report on Monday, July 7th. They issued an “outperform” rating and a $22.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Pulse Biosciences currently has a consensus rating of “Hold” and an average target price of $22.00.

Insider Activity at Pulse Biosciences

In related news, CTO Darrin Uecker sold 25,000 shares of Pulse Biosciences stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $15.77, for a total value of $394,250.00. Following the completion of the transaction, the chief technology officer owned 122,872 shares in the company, valued at approximately $1,937,691.44. This trade represents a 16.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert W. Duggan acquired 34,659 shares of Pulse Biosciences stock in a transaction on Wednesday, September 10th. The shares were bought at an average cost of $14.66 per share, for a total transaction of $508,100.94. Following the completion of the purchase, the director directly owned 47,551,200 shares of the company’s stock, valued at $697,100,592. The trade was a 0.07% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders sold 95,000 shares of company stock valued at $1,550,380. Insiders own 74.60% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Several large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its stake in Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after acquiring an additional 2,156 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after acquiring an additional 680 shares during the last quarter. Brevan Howard Capital Management LP bought a new stake in Pulse Biosciences during the second quarter worth approximately $215,000. Bank of America Corp DE increased its stake in Pulse Biosciences by 0.7% during the second quarter. Bank of America Corp DE now owns 783,536 shares of the company’s stock worth $11,824,000 after acquiring an additional 5,775 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in Pulse Biosciences by 20.6% during the 2nd quarter. Jane Street Group LLC now owns 24,251 shares of the company’s stock valued at $366,000 after purchasing an additional 4,146 shares during the last quarter. 76.95% of the stock is owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.